key: cord-0803982-n1nwzj1x
authors: Al-Jighefee, Hadeel T.; Najjar, Hoda; Ahmed, Muna Nizar; Qush, Abeer; Awwad, Sara; Kamareddine, Layla
title: COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
date: 2021-10-18
journal: Vaccines (Basel)
DOI: 10.3390/vaccines9101196
sha: 2248c349c4d540821ed9a65b08b56e3b97a26d1a
doc_id: 803982
cord_uid: n1nwzj1x

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt the pandemic and alleviate its impact on society, economy, and public health, the development of vaccines and antiviral agents against SARS-CoV-2 was a dire need. To date, various platforms have been utilized for SARS-CoV-2 vaccine development, and over 200 vaccine candidates have been produced, many of which have obtained the United States Food and Drug Administration (FDA) approval for emergency use. Despite this successful development and licensure, concerns regarding the safety and efficacy of these vaccines have arisen, given the unprecedented speed of vaccine development and the newly emerging SARS-CoV-2 strains and variants. In this review, we summarize the different platforms used for Coronavirus Disease 2019 (COVID-19) vaccine development, discuss their strengths and limitations, and highlight the major safety concerns and potential risks associated with each vaccine type.

The coronavirus disease 2019 , caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in late 2019 in Wuhan, the capital of Hubei province in Central China, has become a global pandemic with devastating effects worldwide [1]. Since then, and until 29 June 2021, this newly emerging disease caused by the enveloped SARS-CoV-2 virus, which belongs to the Coronaviridae family and the lineage B of the betacoronavirus (β-CoV) genera, has brought over 181 million confirmed cases and claimed the lives of about 4 million people worldwide [1] . SARS-CoV-2 has a positive-sense, single-stranded genome that encodes a large non-structural polyprotein (ORF1a/b) proteolytically cleaved to generate proteins, four of which are structural proteins including spike (S), envelope (E), membrane (M), and nucleocapsid (N) (Figure 1a) [2, 3] . Among these proteins, the S surface glycoprotein plays a critical role in receptor recognition and attachment to host cells [4] . The S protein also induces T-cell responses and is the main target of highly potent neutralizing antibodies (nAbs) against the virus, presenting it as the major antigenic pick out for vaccine design [5] . The structure of SARS-CoV-2 is similar to other β-CoVs, including the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle Eastern respiratory syndrome-related coronavirus (MERS-CoV), the causative agents of SARS and MERS, two previously reported viral pneumonia disease outbreaks, respectively [6] . Compared to SARS-CoV and MERS-CoV; however, SARS-CoV-2 has higher infectivity and transmissibility due to its high-affinity binding to the host cell receptors and high viral shedding levels during the early stage of infection, contributing Therefore, despite the taken measures and as a consequence of not implementing immediate lockdown, the COVID-19 death toll increased [13, 14] . This necessitated the development of an effective and safe vaccine as an imperative solution to control the pandemic and prevent future outbreaks [13, 15] . As such, and since the release of the SARS-CoV-2 genome sequence in January 2020, all efforts have been directed towards COVID-19 vaccines development [16, 17] . The hope and hype placed on vaccines to prevail over the disease stand up from the success of previously developed vaccines to control other infectious diseases [13] . The route for vaccine development; however, was not always paved, and several historical attempts of vaccines production were doomed with defeats [18] . Until today, and despite all the knowledge and technology at one's disposal, scientists are still unable to conclude the safest and most effective vaccine platform [18] . Back in time, particularly following the outbreak of SARS-CoV in 2002, vaccines against the emerging virus were also developed, a few of which reached phase I clinical trials; yet, did not achieve the final stages and obtain the United States Food and Drug Administration (FDA) approval as the virus was eradicated from the human population in 2004 [16, [19] [20] [21] . Similarly, several vaccines against MERS-CoV were under development, none of which have obtained FDA approved thus far [21] . Within the same notion, and in relay for safe and effective COVID-19 vaccine production, censorious steps are currently followed in all phases of COVID-19 vaccine development, including manufacturing, dispersal, and vaccination [22] . For the time being, many of the newly developed COVID-19 vaccines are undergoing clinical evaluation and have reached phase III of clinical trials. A few of which have been approved for emergency use [13] (Figure 2a , Table 1 ), with the research and discovery phase being skipped [21, 23] . Several approaches, including traditional platforms (inactivated and live attenuated virus vaccines), and newly established ones (replicating and non-replicating viral vector vaccines, nucleic acid (DNA and RNA) vaccines, recombinant subunit vaccines, and peptide-based/virus-like particles vaccines), have been adopted for COVID-19 vaccine development (Figure 1b -h) [16, 24, 25] . As of 29 June 2021, and according to the World Health Organization (WHO), out of the 293 total COVID-19 vaccine candidates, 105 are currently in the clinical phase of development and 184 are still in the pre-clinical phase (Figure 2a ) [26] .Presently, and besides the FDA consideration of the possibility of booster vaccine shots, several standpoints are now advocating the notion that "hybrid immunity" and "the mix and match of different vaccines strategy" could provide an even stronger immune boost, presenting such approaches, if supported by data, as plausible pandemic game-changers. In this review, we detail the different COVID-19 vaccine platforms and highlight their strengths, limitations, and major risks and safety concerns associated with each type, particularly those relevant to the fast-track pace taken for their production. We also summarize all candidate COVID-19 vaccines currently in the clinical phase of development and categorize them according to the platform used for their development. 

Purified inactivated viruses have been widely used for over a century in vaccine development against various emerging infectious diseases, including influenza, polio, rabies, and hepatitis A [27] [28] [29] [30] [31] . Today, inactivated vaccines are typically produced by propagating the virus in cell culture systems, followed by purification, concentration, and chemical and/or physical inactivation to demolish infectivity while retaining immunogenicity ( Figure 1b) [32, 33] . This type of vaccine is notably featured by its highly efficient proliferation and genetic stability [34] ; yet, limited by the viral yield in a cell culture setting, the requirement of a biosafety level 3 facility, and the short duration of the elicited immune response, possibly making the vaccines less effective in preventing viral entry [33, 35] . Up to date, 16 inactivated SARS-CoV-2 vaccines have been developed and are currently in clinical trial phases (Figure 2b ) [26] . One of which, for example, is the Sinovac's CoronaVac vaccine candidate which has demonstrated sufficient safety and efficacy in phase III of clinical trials in Brazil, Turkey, and Indonesia and is currently in phase IV of clinical trials (Table 1) [26, 34, [36] [37] [38] [39] . Another is the BBIBP-CorV vaccine candidate, which showed adequate humoral immune responses in adults aged 18 years and above 

Purified inactivated viruses have been widely used for over a century in vaccine development against various emerging infectious diseases, including influenza, polio, rabies, and hepatitis A [27] [28] [29] [30] [31] . Today, inactivated vaccines are typically produced by propagating the virus in cell culture systems, followed by purification, concentration, and chemical and/or physical inactivation to demolish infectivity while retaining immunogenicity ( Figure 1b) [32, 33] . This type of vaccine is notably featured by its highly efficient proliferation and genetic stability [34] ; yet, limited by the viral yield in a cell culture setting, the requirement of a biosafety level 3 facility, and the short duration of the elicited immune response, possibly making the vaccines less effective in preventing viral entry [33, 35] . Up to date, 16 inactivated SARS-CoV-2 vaccines have been developed and are currently in clinical trial phases (Figure 2b ) [26] . One of which, for example, is the Sinovac's CoronaVac vaccine candidate which has demonstrated sufficient safety and efficacy in phase III of clinical trials in Brazil, Turkey, and Indonesia and is currently in phase IV of clinical trials (Table 1) [26, 34, [36] [37] [38] [39] . Another is the BBIBP-CorV vaccine candidate, which showed adequate humoral immune responses in adults aged 18 years and above and currently stands Vaccines 2021, 9, 1196 5 of 38 in phase IV of clinical trials (Table 1) [39] [40] [41] . Both vaccines have been listed by the WHO for COVID-19 Emergency Use (EUL) and are presently being adopted by several countries worldwide. Despite these promising data, concerns of using inactivated virus vaccines platforms against COVID-19 still reside, some of which relate to the difficulty of confirming a complete virus inactivation status, a risk that could translate into a scenario similar to the 1955 Cutter incident where children receiving the polio vaccine were infected with the inactivated poliovirus [33, 42] . Into the bargain, although several developed inactivated SARS-CoV vaccines have been reported to induce nAbs, vaccinated animals still display significant disease upon challenge, which could explain why no vaccines are currently licensed for SARS-CoV [43] . Further, previous studies on animal models have shown that immunizations with inactivated SARS-CoV and MERS-CoV vaccines are associated with hypersensitive-type lung pathology post-challenges with the infectious virus [32, [44] [45] [46] . Similarly, respiratory syncytial virus (RSV) formalin-inactivated vaccine has been reported to cause enhanced pulmonary disease after live RSV infection [47, 48] . In addition, it was suggested that treating the vaccine with formalin could have altered the epitopes, inducing functional antibodies, causing the immune system to produce antibodies against nonprotective epitopes [33, 49] . It is worth noting here that none of these concerns and/or complications of using inactivated virus vaccines have been thus far reported from the use of recently developed COVID-19 inactivated vaccines.

Live attenuated vaccines, which embody a weakened version of the live virus with reduced virulence, are considered one of the oldest and most effective immunization approaches to elicit life-long immune responses ( Figure 1c ) [32, 50] . A remarkable advantage of such a vaccine type is its relatively low production and delivery costs, given that the attenuated virus can replicate and propagate within the host. As such, a relatively small dose of the virus can be enough to induce immunity [51] . Moreover, live attenuated vaccines can be given intranasally, allowing the attenuated virus to replicate in the mucosal tissue of the upper respiratory tract, a major portal for coronaviruses entry into the host [52] . For the time being, only six SARS-CoV-2 live attenuated virus vaccines have been developed, four of which are in the pre-clinical phase, and two are in phase I of clinical trials ( Figure 2b , Table 1 ) [26] . Both COVI-VAC and MV-014-212 vaccines are attenuated via codon pair deoptimization, a strategy that involves synthetic recoding of the viral genome by amending the positions of synonymous codons, thereby raising the number of suboptimal codon pairs and cytosine phosphoguanine (CpG) dinucleotides in the recoded genome [25, [53] [54] [55] . In parallel to live attenuated SARS-CoV-2 vaccine studies, ongoing studies on other live attenuated virus vaccines such as the RSV vaccine have shown success in using the codon pair deoptimization strategy in vaccine production evidenced by the robust humoral and cellular immune responses triggered in non-human primates [56] .

Despite the aforementioned advantages and the pulled off accomplishments of using live attenuated virus vaccine in combating different infectious diseases, the overt risk of using such a type of vaccine still resides in the use of a live replicating virus, which can revert under any condition to its pathologic phenotype, causing disease after vaccination, especially in immunocompromised individuals [57, 58] . Although this anticipated scenario is considered relatively rare, the degree of unpredictability regarding the virus stability and the arising safety considerations after that should never be ruled out [59] . Further, live attenuated vaccines could result in viral shedding into the environment, posing a potential risk to the unvaccinated community [60] . It also goes without saying that these highlighted disadvantages are acquainted with time consumption and technical difficulties associated with the virus modification approaches if such a vaccine platform is to be implemented [16] .

Viral vector vaccines, in both replicating and non-replicating forms, utilize modified viruses such as adenoviruses or poxviruses as the vector to deliver the genetic material coding for a viral antigen of interest into the host cell ( Figure 1d ) [57, 61] . In self-replicating (replication-competent) viral vector-based vaccines, and through the host cell machinery used by the virus vector, new viral particles are produced in infected cells, which then infect other new cells, resulting in additional vaccine antigen production [62] . On the contrary, non-replicating (replication-incompetent or deficient) viral vector-based vaccines cannot produce new viral particles, and the host cell machinery is used to produce the vaccine antigens, after which the viral vector gets cleared [61, 62] . Both viral vector vaccine forms do not cause infection from neither the loaded virus nor the viral vector as the delivered genetic material does not become integrated into the host genome [61, 63] . Typically, the advantage of this type of vaccine lies in promoting the expression of viral antigens within infected host cells for efficient major histocompatibility complex (MHC) class I and class II presentation [61] . Moreover, viral vectors are characterized by their high gene transduction efficiency, high specificity of genes delivered to target cells, and the immune response they elicit with increased cellular response [64] . Further, although viral vector vaccines are generally considered less robust than traditional vaccine types, the fact that they persist as genetic material in the host, directly infect antigen-presenting cells, and possess a strong inherent adjuvant activity triggering innate and adaptive immune responses and generating high titers of nAbs, could suffice a single vaccine dose for adequate immunization as in the case of the vesicular-stomatitis virus -(VSV)-based Ervebo vaccine against Ebola virus [62, 63, 65] . In COVID-19 vector-based vaccine production, replicating and non-replicating vectors have been utilized to deliver genes encoding for either the SARS-CoV-2 S glycoprotein or the receptor-binding domain (RBD) [16, 26] . Thus far, vaccinia and adenovirus are the predominantly used virus vectors for vectored vaccines development [64] . The adenovirus, for example, has been previously utilized in developing SARS-CoV vaccines expressing the S and N proteins [32, 43, 66] . Currently, it is also being used for developing COVID-19 vectorbased vaccines. Up to date, 4 replicating and 17 non-replicating COVID-19 vector-based vaccines have been developed, of which 2 have reached phase III clinical trials, and 3 are currently in phase IV (Table 1, Figure 2b ) [26] . All five vaccines are adenovirus-based nonreplicating vaccines containing the gene encoding for SARS-CoV-2 S glycoprotein [67] [68] [69] [70] . Among these vaccines, Janssen's (Ad26.COV2.S) vaccine has recently received the FDA EUA for use in in 18 years old and elder individuals after showing good efficacy data in phase III of clinical trials [71] . Although the Ad26.COV2.S vaccine showed around 65-66% efficacy in moderate to severe/critical and around 76-83% in severe/critical COVID-19 patients, its efficacy dropped to 52 and 64% against the Beta (B.1.351) variant in moderate to severe/critical disease conditions, respectively [69] (Table 1) . Low efficacy data were also reported for AstraZeneca vaccine against the Beta variant, with an efficiency of 10.4% only reported in South Africa and 48% in Canada [72, 73] , contrarily to the 70.4% retained efficacy against the Alpha (B.1.1.7) variant as reported in a study conducted in the UK [74] . The other three viral vector vaccines at stages II/III-IV of clinical development are CanSino's adenovirus type-5 (Ad5) vectored vaccine, Gamaleya Research Institute's Gam-COVID-Vac vaccine, and ReiThera's GRAd-COV2 (Table 1) . Although clinical trials have revealed that these vaccines are tolerable and immunogenic, age and the presence of high pre-existing anti-adenovirus immunity were shown to partly diminish vaccination-induced specific antibody and T-cell responses [68] . To overcome pre-existing immunity to the adenovirus in vaccinated individuals, a plausible approach could be using a heterologous recombinant vector as in the Gam-COVID-Vac (Sputnik V) vaccine, the only heterologous COVID-19 vaccine that uses both adenovirus 26 (Ad26) and adenovirus 5 (Ad5) as vectors to express the SARS-CoV-2 S protein [70, 75] . Of note, the general principle of prime-boost with two distinct vectors was not exclusively used in recent COVID-19 vaccine platforms but has been largely implemented experimentally and was also previously used in developing the GamEvac-Combi Ebola virus vaccine [76] . 

In nucleic acid-based vaccines, only the genetic material (DNA or RNA), but not the recombinant/live virus, is taken up by host cells and translated into the protein to elicit an immune response (Figure 1e ,f) [77] . Although various messenger RNA (mRNA) vaccines, including those against influenza, Zika, and rabies viruses, have been thus far developed, this vaccine development platform is still considered relatively new [78] . The pronounced advantage of some types of nucleic acid vaccines generally lies in the largescale production pace and cost [16] . DNA vaccines, for example, are based on the use of highly stable plasmid DNA that can be easily propagated at a large scale in bacteria, as the plasmid DNA typically encloses mammalian expression promoters and the gene encoding the protein of interest [16] . On the other hand, presenting mRNA vaccines as promising alternatives for conventional vaccines mainly lies in the ability to produce the vaccine completely in vivo, along with their high potency, cost-effectiveness, rapid development, and safe delivery [16, 78, 79] . Currently, lipid nanoparticles (LNPs) are among the most commonly used in vivo RNA delivery vectors, protecting the mRNA from enzymatic degradation and facilitating endocytosis and endosomal escape [80] . Contrarily to the highlighted recognition of mRNA vaccines, the physiochemical properties of the mRNA that may impact its cellular and organ dispersal, the questioned safety and efficacy of mRNA vaccine use in humans, them being unlikely to induce strong mucosal immunity due to their intramuscular administration, and the uncertainty from what could arise with large-scale production, storage, and stability are among the alarming concerns tailored to mRNA vaccines production [16, 57, 80] . Likewise, potential disadvantages also relate to DNA vaccines, particularly those relevant to their low immunogenicity and to the need of DNA molecules to traverse the nuclear membrane to be transcribed, necessitating complicated delivery systems such as electroporators for better efficiency [16, 57] . In addition, introducing mutation and dysregulated gene expression by the plausible stable integration of transfected DNA into the somatic or germline host cells genome is another arising concern [81] though unconventional as per relevant follow-up studies [82] [83] [84] [85] . Up to date, 28 nucleic acids (10 DNA and 18 mRNA)-based COVID-19 vaccines have been developed and are currently in the clinical stages, and 24 mRNA vaccines are in the pre-clinical stage ( Figure 2b , Table 1 ) [26] . Two mRNA-based vaccines, developed by Pfizer/BioNTech and Moderna, are currently in phase IV clinical trials and have received the FDA EUA for protection against COVID-19 [26, 86, 87] . Preliminary results showed astoundingly 94-95% efficacy for both vaccines [88, 89] . Though promising, a major concern relevant to mRNA vaccines resides in their rapid pace of development and the uncertainty of potential longterm adverse effects associated with them, particularly because these are the first approved mRNA vaccines with no other FDA-approved mRNA vaccines to date [90] . Another concern is the efficacy of these vaccines against the newly emerging SARS-CoV-2 variants with mutations in the S protein, the main target in COVID-19 vaccines development [91] . As of yet, Pfizer/BioNTech COVID-19 vaccine was reported to protect against four variants of concern (VOCs), including Alpha, Beta, Gamma, and Delta (Table 1) [91] [92] [93] [94] . Interestingly, a recent study by Zakhartchouk et al. reported that combining DNA vaccine and whole killed virus vaccines augments immune responses to SARS-CoV [95] , a propitious tactic worth considering in ongoing COVID-19 vaccine development approaches [95] .

As compared to the whole-pathogen vaccine platform, a protein subunit vaccine is composed of in vitro harvested and highly purified viral protein antigens carefully chosen for their ability to elicit an immune response (Figure 1g ) [96] . Being incapable of causing disease, the protein subunit vaccine platform is considered safer than the whole-virus (live attenuated and inactivated) platforms [97] . Not displaying the full antigenic complexity of the virus and enclosing small antigens deficient of pathogen-associated molecular patterns (PAMPs); however, it may promote skewed immune responses, bringing the immunogenicity potential and protective efficacy of protein subunit vaccines into question [57, 97] . Subunit vaccine design and production could be also costly and might necessitate specific adjuvants to boost the immune response [98] , in addition to the potential occurrence of antigen denaturation, which could lead to non-specific binding [99] . Examples of developed subunit vaccines include the recombinant RBD subunit vaccine, which was reported to elicit partial protective immunity in rhesus macaques against MERS-CoV challenge [100] , and S protein-based subunit vaccines against SARS-CoV infection with potency to induce nAbs and protect against SARS-CoV intranasal infection in mice [32, 101] . Up to date, 33 COVID-19 protein subunit vaccines based on the S protein or the RBD have been developed and are in the clinical stages. Of which, 10 vaccines, including Novavax's (NVX-CoV2373) are in phase III [26, 102] . Recent reports showed that a two-dose regimen of the NVX-CoV2373 vaccine exhibited 89.7% efficacy against SARS-CoV-2 infection, with high efficacy against the Alpha, Beta, and other VOCs [102, 103] (Table 1) . Virus-like particles (VLPs) vaccine is another type of protein-based vaccine composed of proteins from the viral capsid only with no viral genetic material (Figure 1h ) [57, 104] . In addition to being safe, VLPs elicit potent immune responses due to their repetitive structures [104] . VLP vaccines against many viruses, including Hepatitis B virus, Human papillomaviruses, and Influenza A virus, do exist [104] [105] [106] [107] . Likewise, VLP vaccines against MERS-CoV and SARS-CoV infection have been also developed, with eosinophilic pulmonary immunopathology detected after viral challenge in some cases [21, 46, 108] . For the COVID-19 status quo particularly, five VLPs vaccines in different phases of clinical trials are thus far available ( Figure 2b , Table 1 ) [26] . NR Not yet approved in any country [26, 133] Vaccines 2021, 9, 1196 NR Not yet approved in any country [26, 180] Vaccines 2021, 9, 1196 [26, 73, 88, 92, 94, 110, 137, 145, [194] [195] [196] [197] [198] [26, 73, 89, 92, 93, 110, 141, 142, 145, 196, 197, [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] NR Not yet approved in any country [26, 227] Vaccines 2021, 9, 1196 NR Not yet approved in any country [26, 278] Vaccines 2021, 9, 1196 NR Not yet approved in any country [26, 296] 

WHO. WHO Coronavirus Disease (COVID-19) Dashboard. Available online

Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

Coronavirus biology and replication: Implications for SARS-CoV-2

Structural insights into coronavirus entry

A comparison of COVID-19, SARS and MERS

The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics

SARS-CoV-2 and immunemicrobiome interactions: Lessons from respiratory viral infections

COVID-19: Prevention and control measures in community

COVID-19 herd immunity: Where are we?

Antibodies, Immunity, and COVID-19

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

Herd immunity or suppression strategy to combat COVID-19

Herd Immunity: Understanding COVID-19

SARS-CoV-2 vaccines in development

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)

COVID-19 vaccines: Where we stand and challenges ahead

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine

Coronavirus vaccine development: From SARS and MERS to COVID-19

The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation

Developing Covid-19 Vaccines at Pandemic Speed

Fundamentals of vaccine immunology

SARS-CoV-2 Vaccine Development: Current Status

Draft Landscape of COVID-19 Candidate Vaccines

Inactivated poliovirus vaccine: Past and present experience

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Development of an inactivated vaccine candidate for SARS-CoV-2

Chapter 13-Rabies Vaccines

Inactivated hepatitis A vaccine: Immunogenicity, efficacy, safety and review of official recommendations for use

A decade after SARS: Strategies for controlling emerging coronaviruses

Inactivated Viral Vaccines

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Chapter 11-Vaccines and Vaccination

Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19; NIH: Bethseda

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial

Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated (COVID-19)

The cutter incident. poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the united states during the spring of 1955. II. Relationship of poliomyelitis to cutter vaccine

SARS vaccines: Where are we?

Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum. Vaccines Immunother

A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge

Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus

Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity

Engineering attenuated virus vaccines by controlling replication fidelity

23-Vaccines and Clinical Immunization

Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?

Mechanism of Virus Attenuation by Codon Pair Deoptimization

Virus Attenuation by Genome-Scale Changes in Codon Pair Bias

Meissa Vaccines-MV-014-212

A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates

A systematic review of SARS-CoV-2 vaccine candidates

Chapter 26-Vaccines: Present Status and Applications

MODULE 2 Types of Vaccine and Adverse Reactions

Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children

Replication-defective viruses as vaccines and vaccine vectors

Replicating and non-replicating viral vectors for vaccine development

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial

Developments in Viral Vector-Based Vaccines

Next-generation vaccine platforms for COVID-19

Effects of a SARS-associated coronavirus vaccine in monkeys

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sputnik V COVID-19 vaccine candidate appears safe and effective

Food and Drug Administration

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

Safety and immunogenicity of GamEvac-Combi, a heterologous VSV-and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia

The promise of nucleic acid vaccines

mRNA vaccines-A new era in vaccinology

An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development

Blankschtein, D. mRNA vaccine delivery using lipid nanoparticles

Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models

DNA Vaccines-How Far From Clinical Use?

Long-term persistence of plasmid DNA and foreign gone expression in mouse muscle

Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation

Plasmid DNA vaccines: Tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA

Pfizer-BioNTech COVID-19 Vaccine

Food and Drug Administration. Moderna COVID-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Things about mRNA COVID Vaccines Researchers Still Want to Find out

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Effectiveness of COVID-19 Vaccines against Hospital Admission with the Delta (B.1.617.2) Variant

Vaccines 2021

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines

Development of subunit vaccines against severe acute respiratory syndrome

Sola, I. Molecular Basis of Coronavirus Virulence and Vaccine Development

Chapter 1-Biotechnologies for the Management of Genetic Resources for Food and Agriculture

Vaccine Safety Basics

Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge

Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Novavax Vaccine Results: How Effective is it against Variants?

Production of virus-like particles for vaccines

A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial

Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV

WHO. Interim Recommendations for Use of the Inactivated COVID-19 Vaccine, CoronaVac, Developed by Sinovac. Available online

Status of COVID-19 Vaccines within WHO EUL/PQ Evaluation Process

Document on the Inactivated Vaccine Sinovac-CoronaVac against COVID-19

More data for regulators and policy makers

WHO. Interim Recommendations for Use of the Inactivated COVID-19 Vaccine BIBP Developed by China National Biotec Group (CNBG), Sinopharm. Available online

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials

A Phase III Clinical Trial for Inactivated Novel Coronavirus Pneumonia (COVID-19) Vaccine (Vero Cells)

An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine

Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

Efficacy and Safety of QazCovid-in®COVID-19 Vaccine

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial

COVAXIN®-India's First Indigenous COVID-19 Vaccine

An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers

Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): A, double-blind, randomised

Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells)

Study To Compare the Immunogenicity Against COVID-19, of VLA2001 Vaccine to AZD1222 Vaccine (COV-COMPARE)

Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine

Placebo-Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of COVID-19 Inactivated Vaccine (Shifa-Pharmed) in a Population Aged 18 to 75 Years

Phase 2 Trial of Safety and Immunogenicity of 10 Micro Gram Inactivated SARS-CoV-2 Vaccine (FAKHRAVAC), Two Doses Two Weeks Apart in Adults Aged 18-70 Years: A Randomized, Double-Blind, Placebo-Controlled

A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine

Comparative Study to Evaluate the Safety and Immunogenicity of KD-414, a Vaccine Against COVID-19, in Healthy Adults Aged ≥20 Years to <65 Years, and Healthy Elderly Subjects Aged ≥65 Years

Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo

Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults (COVID-19)

Study of a Live rNDV Based Vaccine against COVID-19

Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine against COVID-19

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE) (ENFORCE)

Vaccines 2021

Africa Regulatory Taskforce Has Endorsed the Emergency Used Listing for Two Versions of the AstraZeneca-Oxford Vaccine

COVID-19 Vaccine Update

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: A national prospective cohort study

Covid vaccine: AstraZeneca Updates US Vaccine Efficacy Results

Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa

Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)

Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

CanSinoBIO's COVID-19 Vaccine 65.7% Effective in Global Trials

A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial

African Union and the Africa CDC's Africa Regulatory Taskforce Has Endorsed the Emergency Used Authorization for Janssen COVID-19 Vaccine

Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia

Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 (RESIST)

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia

World News. Sputnik V Gives 90% Protection against Delta Strain of Covid-19

Study of GRAd-COV2 for the Prevention of COVID-19 in Adults (COVITAR)

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

GRAd-COV2, a gorilla adenovirus based candidate vaccine against COVID-19, is safe and immunogenic in young and older adults

Immunity and Safety of Covid-19 Synthetic Minigene Vaccine

COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines

ImmunityBio targets cancer and COVID-19. Biopharma Deal. 2021. Available online

A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses

Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers

Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC

Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 (MVA-SARS-2-ST)

Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults

Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection

NIH. Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study

Synthetic MVA-Based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19

Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines against SARS-CoV-2 in Healthy Adults

NIH. A Phase 1, First-in-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers. Available online

Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19

The Nasal Spray Influenza Virus Vector New Coronary Pneumonia (COVID-19) Vaccine (DelNS1-2019-nCoV-RBD-OPT1) Phase II Clinical Trial

Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge

Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults

Safety and Immunity of Covid-19 aAPC Vaccine

Randomized, Adaptive, Phase I/II Clinical Study to Evaluate the Safety and Immunogenicity of Novel Corona Virus -2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by Intradermal Route in Healthy Subjects

Covid-19 vaccine shows 66.6% efficacy, seeks DCGI approval

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure

Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure

NIH. Phase II/III Study of COVID-19 DNA Vaccine

Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults

Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults

Nucleic Acid Vaccines

GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)

Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19

SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2) (CORVax12)

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19

The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers (COVALIA)

Vaccines and Related Biological Products Advisory Committee Meeting

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers-Eight

Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines

Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario

Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study)

FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age population-First results from a cohort study in Southern Sweden

Annex A: Report to JCVI on estimated efficacy of a single dose of Pfizer BioNTech (BNT162b2 mRNA) vaccine and of a single dose of ChAdOx1 vaccine (AZD1222)

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization

Valentiner-Branth, P. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers-A Danish cohort study

The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: Real-world evidence

SARS-CoV-2 Vaccines

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19

CureVac's mRNA-based vaccine candidate against COVID-19

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above

A Thermostable mRNA Vaccine against COVID-19

Study to Evaluate the Immunogenicity and Safety of mRNA-1273.211 Vaccine for COVID-19 Variants

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults

Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

Arcturus-A Clinical-Stage mRNA Therapeutics and Vaccines Company. Biopharma Deal

Study of mRNA Vaccine Formulation against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)

Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models

Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate

Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects

COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials

Safety and Immunogenicity of EXG-5003

Clinical Trial to Assess the Safety of a Coronavirus Vaccine in Healthy Men and Women

COVAC1: How the Trial Works

The Latest Development in ChulaCov19 Vaccine

ChulaCov19 mRNA Vaccine in Healthy Adults

This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64

CoV-2 mRNA Vaccine PTX-COVID19-B Safe and Highly Immunogenic in Preclinical Study

Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults

Phase 1 Study to Assess Safety, Reactogenicity and Immunogenicity of the HDT-301 Vaccine Against COVID-19

Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna's Next Generation

Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of mRNACOVID-19 Vaccine in Healthy Susceptible Populations Aged 18 Years and Older People

Stemirna Raises Nearly $200M to Advance mRNA COVID-19 Vaccine

Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine against SARS-CoV-2, the Causative Agent of COVID-19 (COVAC-Uganda)

Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥18 Years With a Pediatric Expansion in Adolescents (12-17 Years) at Risk for SARS-CoV-2

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)

Sanofi and GSK Initiate Global Phase 3 Clinical Efficacy Study of COVID-19 Vaccine Candidate

Encouraged by Early Efficacy Results of Homegrown COVID-19 Vaccine

RPCEC. SOBERANA 02-FaseIII. Available online

A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents

Global Phase III Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells)

Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19

More Russian Vaccines: What We Do and Don't Know

Covid-19: Russian vaccine efficacy is 91.6%, show phase III trial results

Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19

Vaccines 2021

Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: A phase 1, randomised, double-blind, placebo-controlled trial

Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine

Placebo Controlled Trial to Evaluate Efficacy and Safety of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine (SpikoGen®) Produced by CinnaGen Co. (Two doses of 25 µg with Dosing Interval of 21 days)

Available online: https:// clinicaltrials.gov/ct2/show/NCT04695652 (accessed on

Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults

Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study

Safety and Immunogenicity of RAZI SARS-CoV-2 Recombinant Spike Protein Vaccine (RAZI Cov Pars) in Adults Aged 18-70 Years; a Randomised, Double Blind, parallel 2 Arms Clinical Trial

Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Subjects

BAT Progresses COVID-19 Candidate Vaccine into Phase I Human Clinical Trials

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

Biological E's Novel Covid-19 Vaccine of SARS-CoV-2 for Protection against Covid-19 Disease

Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of S-268019 in Japanese Adult Participants

Clinical Trial of COVAC-2 in Healthy Adults

NIH. Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted with Aluminum Hydroxide (COVID-19). Available online

Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine

Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults

Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19

Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: A randomised, double-blind, placebo-controlled, phase 1 trial

Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)

Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine

Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)

Reactogenicity and Immunogenicity Study of ReCOV

SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults

Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates

A spike-ferritin nanoparticle vaccine induces robust innate immune activity and drives polyfunctional SARS-CoV-2-specific T cells

To Evaluate the Safety, and Immunogenicity of Vaccine Candidate against COVID-19

First-in-Human Study Of Orally Administered CoV2-OGEN1 in Healthy Subjects

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

A Phase 1/2 Randomized, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine in Healthy Adults

Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate (VBI-2902a)

Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-Like Particle (VLP) Vaccine in Healthy Adults (COVID-19)

Safety and Tolerability of COVID-19 Vaccine (ABNCoV2) (COUGH-1)